Embecta Corp Up 3.61% To $16.92 After Earnings

Embecta Corp (EMBC) said before open Tuesday that it broke even in quarter four 2023.

In the same quarter a year ago, the company earned $0.73 per share on revenue of $274.6 million.

The stock is up 3.61% to $16.92 after the report.

The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.

Wall Street Analysts had an average rating of Sell on the stock prior to the report.

Trading in the five days leading up to the report earned Embecta Corp a Bullish Sentiment Rank from InvestorsObserver.

Embecta Corp has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 14, putting Embecta Corp in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $12.72 on October 3, 2023 and set a 52-week high on December 14, 2022 at $36.64.

Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.